cancer target detection radiopharma radio
Biotech

Nuvalent trots out strong pivotal data in FDA lung cancer push

Nuvalent is eyeing an FDA rolling submission for its ROS1 inhibitor in TKI-pretreated lung cancer after releasing competitive pivotal data.
Angus Liu Jun 24, 2025 6:30am
United Kingdom UK UK
Favicon Fierce Pharma

UK reveals life sciences plan in sweeping strategy update

Jun 23, 2025 3:55pm
head to head against clash football helmets fight combat

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

Jun 23, 2025 2:30pm
FDA
Favicon Fierce Pharma

FDA's acting CDER head heads for the exit: report

Jun 23, 2025 1:48pm
eye doctor opthalmology phoropter glasses eye disease vision

J&J launches daily contact lens for astigmatism, presbyopia

Jun 23, 2025 11:48am
artistic visualization of genome data genetics

Illumina picks up proteomics developer SomaLogic for $425M

Jun 23, 2025 11:00am
More News

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor

Jun 23, 2025 9:47am

Fierce Biotech Layoff Tracker 2025: Prothena, BioNTech & more

Jun 23, 2025 9:30am

Leap expands layoffs to 75% of staff, scraps last clinical trial

Jun 23, 2025 9:22am

Corxel, Sciwind post data as China's obesity push gathers pace

Jun 23, 2025 9:20am